Navigation Links
Watson Confirms Testim® Patent Challenge

PARSIPPANY, N.J., May 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim® 1%. Testim®1% is indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Auxilium Pharmaceuticals, Inc. and FCB I LLC filed suit against Watson on May 23, 2012 in the United States District Court for the District of New Jersey seeking to prevent Watson from commercializing its 1% testosterone gel product prior to the expiration of certain U.S. patents.  The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending March 31, 2012, Testim® had total U.S. sales of approximately $260 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology.  Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

Forward-Looking Statement 
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and Watson's Annual Report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Testim® is a registered trademark of Auxilium Pharmaceuticals, Inc.CONTACTS:  Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: )


SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Freudenberg Medical has developed specialty tubing for ... of medical facilities. Africa and ... is sparse. Nevertheless, prompt diagnosis is important to treat those ... virus. With the help of a portable mini-lab or "lab ... village in affected areas and perform rapid testing for HIV. ...
(Date:11/24/2015)... November 24, 2015 Edelris announce today ... co-own with Inserm, Poxel, CNRS, UCBL and ENS-Lyon on a ... --> Hepatitis B virus (HBV) infection is ... people chronically infected worldwide, 20 to 40% of them being ... carcinoma. Despite the existence of an effective preventive vaccine, the ...
(Date:11/24/2015)... Ill. , Nov. 24, 2015  Wellness Center USA ... November shipments of its flagship product, Psoria-Light® (PL 1000), to targeted dermatology ... Houston, Minnesota , and North Carolina ... Cleveland , Chicago , and ... --> Revenue for the earlier shipments reported on October ...
Breaking Medicine Technology:
(Date:11/24/2015)... FL (PRWEB) , ... November 24, 2015 , ... In ... a growing epidemic as deaths from prescription opioids in the United States grew 400 ... cocaine. In 2013 alone, opioids were involved in 37 percent of all fatal drug ...
(Date:11/24/2015)... ... , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse located ... the staff members at their recovery center. The videos highlight some of the various ... the things that make their recovery program so unique. , “Making the decision to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Chiropractic student Katie Benson received ... in Overland Park, Kansas. Benson, a fifth-trimester student in the university’s College of ... on October 16. , “Katie is very excited and greatly appreciative to receive ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science ... social media and the generosity of people around the world. On December 1, supporters ... to give – and share the personal stories behind those gifts. , Just ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... ... and engineer of patented products, announces Fragrance by Marcelle, a cosmetic invention which ... The Perfume & Fragrance Manufacturing Market in the US is worth $3 billion ...
Breaking Medicine News(10 mins):